Low endoscopy bleeding risk in patients with congenital bleeding disorders.
Antifibrinolytic Agents
/ therapeutic use
Blood Coagulation Disorders, Inherited
/ pathology
Coagulants
/ therapeutic use
Endoscopy, Digestive System
/ adverse effects
Female
Hemorrhage
/ etiology
Humans
Logistic Models
Male
Middle Aged
Odds Ratio
Retrospective Studies
Risk
Severity of Illness Index
Tranexamic Acid
/ therapeutic use
congenital bleeding disorders
gastrointestinal endoscopy
gastrointestinal haemorrhage
haemophilia
rare inherited bleeding disorders
von Willebrand disease
Journal
Haemophilia : the official journal of the World Federation of Hemophilia
ISSN: 1365-2516
Titre abrégé: Haemophilia
Pays: England
ID NLM: 9442916
Informations de publication
Date de publication:
Mar 2019
Mar 2019
Historique:
received:
18
04
2018
revised:
06
06
2018
accepted:
17
01
2019
pubmed:
13
2
2019
medline:
30
4
2019
entrez:
13
2
2019
Statut:
ppublish
Résumé
Haemophilia A and haemophilia B, von Willebrand disease (VWD), factor VII deficiency and factor XI deficiency are congenital bleeding disorders predisposing to bleeding during invasive procedures. The ageing population of people with congenital bleeding disorders will likely increasingly require gastrointestinal endoscopy. The bleeding risk postgastrointestinal endoscopy and optimal prophylactic treatment regimens are not well described. We performed a retrospective chart review at the McGill University Health Centre. Adult patients with haemophilia A or B, VWD, FVII deficiency and FXI deficiency who underwent gastrointestinal endoscopic procedures were included. Bleeding prophylaxis included combinations of plasma-derived factor (VWD) or recombinant factor (haemophilia A and haemophilia B), desmopressin and/or tranexamic acid. Our primary outcome was the 72-hour postendoscopy bleeding rate. One hundred and four endoscopies were performed in 48 patients. Haemophilia A (45.3% of endoscopies) was the most common bleeding disorder, followed by VWD (38.5%), FXI deficiency (8.7%), haemophilia B (4.8%) and FVII deficiency (2.9%). All patients were reviewed by the Haemophilia Treatment Center with peri-procedure treatment protocols put in place as required. The overall 72-hour bleeding rate was 0.96%, confidence interval (CI) 95% (0.17%-5.25%). The colonoscopic postpolypectomy bleeding rate was 1/21 (4.8%, CI 95% (0.9%-22.7%)) in comparison with the general population rate of 0.3%-10% for high-risk endoscopy (including colonoscopic polypectomy). To the best of our knowledge, this is the largest study describing patients with inherited bleeding disorders undergoing gastrointestinal endoscopy. The bleeding risk is not significantly higher to the general population when haemostatically managed by a team experienced in bleeding disorders.
Substances chimiques
Antifibrinolytic Agents
0
Coagulants
0
Tranexamic Acid
6T84R30KC1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
289-295Informations de copyright
© 2019 John Wiley & Sons Ltd.